{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:36:44Z","timestamp":1793140604755,"version":"4.5.0"},"reference-count":97,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,5]]},"abstract":"<jats:p>Extraintestinal manifestations (EIMs) are common in inflammatory bowel disease (IBD), in both Crohn\u2019s disease and ulcerative colitis. Almost any organ system can be affected, including the musculoskeletal, dermatologic, renal, hepatopancreatobiliary, pulmonary and ocular systems. However, the musculoskeletal and dermatologic systems are the most commonly involved sites of manifestations. While some manifestations such as peripheral arthritis and erythema nodosum have an association with IBD activity, others such as axial arthropathy, pyoderma gangrenosum and primary sclerosing cholangitis have an independent disease course. This review provides a summary of the most common EIMs in IBD and their prevalence and management.<\/jats:p>","DOI":"10.4103\/sjmms.sjmms_81_18","type":"journal-article","created":{"date-parts":[[2019,4,12]],"date-time":"2019-04-12T06:01:59Z","timestamp":1555048919000},"page":"66-73","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":52,"title":["A Review of Extraintestinal Manifestations and Complications of Inflammatory Bowel Disease"],"prefix":"10.4103","volume":"7","author":[{"given":"Vito","family":"Annese","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Valiant Clinic, Dubai, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2019,4,12]]},"reference":[{"key":"R1-20250525","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nrgastro.2013.117","article-title":"Extraintestinal manifestations and complications in IBD","volume":"10","author":"Ott","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R2-20250525","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/ibd.20604","article-title":"Development of extraintestinal manifestations in pediatric patients with inflammatory bowel disease","volume":"15","author":"Jose","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"R3-20250525","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/ajg.2010.343","article-title":"Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort","volume":"106","author":"Vavricka","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"R4-20250525","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1136\/ard.2009.108233","article-title":"The development of assessment of spondyloArthritis international society classification criteria for axial spondyloarthritis (part II): Validation and final selection","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R5-20250525","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1440-1746.2007.05108.x","article-title":"Clinical and genetic factors associated with sacroiliitis in Crohn\u2019s disease","volume":"23","author":"Peeters","year":"2008","journal-title":"J Gastroenterol Hepatol"},{"key":"R6-20250525","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1111\/apt.12680","article-title":"The prevalence of inflammatory sacroiliitis assessed on magnetic resonance imaging of inflammatory bowel disease: A retrospective study performed on 186 patients","volume":"39","author":"Leclerc-Jacob","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"R7-20250525","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/acr.23323","article-title":"Prevalence of sacroiliitis in inflammatory bowel disease using a standardized computed tomography scoring system","volume":"70","author":"Chan","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R8-20250525","doi-asserted-by":"crossref","first-page":"5517","DOI":"10.3748\/wjg.15.5517","article-title":"Rheumatic manifestations of inflammatory bowel disease","volume":"15","author":"Rodr\u00edguez-Reyna","year":"2009","journal-title":"World J Gastroenterol"},{"key":"R9-20250525","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/ecco-jcc\/jjv213","article-title":"The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease","volume":"10","author":"Harbord","year":"2016","journal-title":"J Crohns Colitis"},{"key":"R10-20250525","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1365-2036.2008.03868.x","article-title":"The prevalence, clinical features and association of HLA-B27 in sacroiliitis associated with established Crohn\u2019s disease","volume":"29","author":"Orchard","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"R11-20250525","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1136\/gut.42.3.387","article-title":"Peripheral arthropathies in inflammatory bowel disease: Their articular distribution and natural history","volume":"42","author":"Orchard","year":"1998","journal-title":"Gut"},{"key":"R12-20250525","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1155\/2001\/612531","article-title":"Muscoloskeletal manifestations in inflammatory bowel disease","volume":"15","author":"Fornaciari","year":"2001","journal-title":"Can J Gastroenterol"},{"key":"R13-20250525","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1080\/003655201317097173","article-title":"Musculoskeletal manifestations in a population-based cohort of inflammatory bowel disease patients","volume":"36","author":"Salvarani","year":"2001","journal-title":"Scand J Gastroenterol"},{"key":"R14-20250525","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s10620-010-1260-z","article-title":"Peripheral arthritis in the course of inflammatory bowel diseases","volume":"56","author":"Y\u00fcksel","year":"2011","journal-title":"Dig Dis Sci"},{"key":"R15-20250525","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1136\/ard.2010.145995","article-title":"Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis","volume":"70","author":"Poddubnyy","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"R16-20250525","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1136\/annrheumdis-2011-201252","article-title":"Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: Results from the German Spondyloarthritis Inception Cohort","volume":"71","author":"Poddubnyy","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"R17-20250525","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1007\/s11926-012-0282-2","article-title":"Biologic therapies for spondyloarthritis: What is new?","volume":"14","author":"Baraliakos","year":"2012","journal-title":"Curr Rheumatol Rep"},{"key":"R18-20250525","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1136\/annrheumdis-2012-202698","article-title":"Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis","volume":"73","author":"Baraliakos","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R19-20250525","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1002\/art.38070","article-title":"The impact of tumor necrosis factor \u03b1 inhibitors on radiographic progression in ankylosing spondylitis","volume":"65","author":"Haroon","year":"2013","journal-title":"Arthritis Rheum"},{"key":"R20-20250525","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1136\/annrheumdis-2011-200859","article-title":"Suppression of inflammation and effects on new bone formation in ankylosing spondylitis: Evidence for a window of opportunity in disease modification","volume":"72","author":"Maksymowych","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R21-20250525","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/annrheumdis-2012-201766","article-title":"Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: Results of a randomised placebo-controlled trial (ABILITY-1)","volume":"72","author":"Sieper","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R22-20250525","first-page":"CD004800","article-title":"Sulfasalazine for ankylosing spondylitis","author":"Chen","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"R23-20250525","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1093\/rheumatology\/kes066","article-title":"First update of the current evidence for the management of ankylosing spondylitis with non-pharmacological treatment and non-biologic drugs: A systematic literature review for the ASAS\/EULAR management recommendations in ankylosing spondylitis","volume":"51","author":"van den Berg","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"R24-20250525","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1002\/art.1780391209","article-title":"Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs Cooperative Study","volume":"39","author":"Clegg","year":"1996","journal-title":"Arthritis Rheum"},{"key":"R25-20250525","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/art.1780380507","article-title":"Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study","volume":"38","author":"Dougados","year":"1995","journal-title":"Arthritis Rheum"},{"key":"R26-20250525","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.crohns.2008.01.005","article-title":"Osteoporosis in inflammatory bowel disease","volume":"2","author":"Reinshagen","year":"2008","journal-title":"J Crohns Colitis"},{"key":"R27-20250525","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.maturitas.2008.11.022","article-title":"Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK","volume":"62","author":"Compston","year":"2009","journal-title":"Maturitas"},{"key":"R28-20250525","doi-asserted-by":"crossref","first-page":"99","DOI":"10.7326\/0003-4819-153-2-201007200-00262","article-title":"Screening for osteoporosis: An update for the U.S. preventive services task force","volume":"153","author":"Nelson","year":"2010","journal-title":"Ann Intern Med"},{"key":"R29-20250525","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.cgh.2007.02.024","article-title":"Vertebral fractures and role of low bone mineral density in Crohn\u2019s disease","volume":"5","author":"Siffledeen","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R30-20250525","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1136\/gut.51.5.654","article-title":"High prevalence of osteoporotic vertebral fractures in patients with Crohn\u2019s disease","volume":"51","author":"Klaus","year":"2002","journal-title":"Gut"},{"key":"R31-20250525","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1046\/j.1365-2036.2002.01317.x","article-title":"Discordance between the degree of osteopenia and the prevalence of spontaneous vertebral fractures in Crohn\u2019s disease","volume":"16","author":"Stockbr\u00fcgger","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"R32-20250525","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1097\/00042737-200312000-00003","article-title":"Bone density improves with disease remission in patients with inflammatory bowel disease","volume":"15","author":"Reffitt","year":"2003","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R33-20250525","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1111\/j.1572-0241.2005.50219.x","article-title":"Maintenance infliximab treatment is associated with improved bone mineral density in Crohn\u2019s disease","volume":"100","author":"Bernstein","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"R34-20250525","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1177\/153537020422901108","article-title":"Mounting evidence for vitamin D as an environmental factor affecting autoimmune disease prevalence","volume":"229","author":"Cantorna","year":"2004","journal-title":"Exp Biol Med (Maywood)"},{"key":"R35-20250525","doi-asserted-by":"crossref","first-page":"1717S","DOI":"10.1093\/ajcn\/80.6.1717S","article-title":"Vitamin D status, 1,25-dihydroxyvitamin D3, and the immune system","volume":"80","author":"Cantorna","year":"2004","journal-title":"Am J Clin Nutr"},{"key":"R36-20250525","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/j.1365-2036.2012.05181.x","article-title":"Review article: Vitamin D and inflammatory bowel disease \u2013 Established concepts and future directions","volume":"36","author":"Garg","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"R37-20250525","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1002\/ibd.21595","article-title":"Use of a novel Vitamin D bioavailability test demonstrates that Vitamin D absorption is decreased in patients with quiescent Crohn\u2019s disease","volume":"17","author":"Farraye","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"R38-20250525","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1111\/j.1572-0241.2007.01753.x","article-title":"Vitamin D status and bone density in recently diagnosed inflammatory bowel disease: The Manitoba IBD Cohort Study","volume":"103","author":"Leslie","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"R39-20250525","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1001\/archopht.1997.01100150063010","article-title":"Uveitis associated with inflammatory bowel disease compared with uveitis associated with spondyloarthropathy","volume":"115","author":"Lyons","year":"1997","journal-title":"Arch Ophthalmol"},{"key":"R40-20250525","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3109\/07853890903559724","article-title":"Extraintestinal manifestations of inflammatory bowel disease: Epidemiology, diagnosis, and management","volume":"42","author":"Larsen","year":"2010","journal-title":"Ann Med"},{"key":"R41-20250525","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/00054725-200403000-00012","article-title":"Ocular manifestations of inflammatory bowel disease","volume":"10","author":"Mintz","year":"2004","journal-title":"Inflamm Bowel Dis"},{"key":"R42-20250525","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000353375","article-title":"Managing IBD outside the gut: Ocular manifestations","volume":"31","author":"Calvo","year":"2013","journal-title":"Dig Dis"},{"key":"R43-20250525","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3109\/09273940903072443","article-title":"Clinical review: Anti-TNF alpha therapies in uveitis: Perspective on 5 years of clinical experience","volume":"17","author":"Sharma","year":"2009","journal-title":"Ocul Immunol Inflamm"},{"key":"R44-20250525","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/ICU.0b013e3282f03d42","article-title":"Biologics in the treatment of uveitis","volume":"18","author":"Imrie","year":"2007","journal-title":"Curr Opin Ophthalmol"},{"key":"R45-20250525","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.ophtha.2013.09.048","article-title":"Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders","volume":"121","author":"Levy-Clarke","year":"2014","journal-title":"Ophthalmology"},{"key":"R46-20250525","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1155\/2005\/323914","article-title":"Erythema nodosum and pyoderma gangrenosum in 50 patients with Crohn\u2019s disease","volume":"19","author":"Freeman","year":"2005","journal-title":"Can J Gastroenterol"},{"key":"R47-20250525","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1111\/j.1572-0241.2006.00504.x","article-title":"Inflammatory bowel disease characteristics among African Americans, hispanics, and non-hispanic whites: Characterization of a large North American cohort","volume":"101","author":"Nguyen","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"R48-20250525","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/MD.0b013e318187cc9c","article-title":"Significance of erythema nodosum and pyoderma gangrenosum in inflammatory bowel diseases: A cohort study of 2402 patients","volume":"87","author":"Farhi","year":"2008","journal-title":"Medicine (Baltimore)"},{"key":"R49-20250525","doi-asserted-by":"crossref","first-page":"79","DOI":"10.5114\/reum.2016.60217","article-title":"Erythema nodosum \u2013 Review of the literature","volume":"54","author":"Chowaniec","year":"2016","journal-title":"Reumatologia"},{"key":"R50-20250525","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1136\/pgmj.2004.031633","article-title":"Important cutaneous manifestations of inflammatory bowel disease","volume":"81","author":"Trost","year":"2005","journal-title":"Postgrad Med J"},{"key":"R51-20250525","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/j.1365-2230.2006.02221.x","article-title":"Treatment of chronic erythema nodosum with infliximab","volume":"31","author":"Clayton","year":"2006","journal-title":"Clin Exp Dermatol"},{"key":"R52-20250525","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/j.1468-3083.2006.01893.x","article-title":"Refractory chronic erythema nodosum successfully treated with adalimumab","volume":"21","author":"Ortego-Centeno","year":"2007","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R53-20250525","first-page":"88","article-title":"Clinical manifestations of pyoderma gangrenosum associated with inflammatory bowel disease","volume":"6","author":"Menachem","year":"2004","journal-title":"Isr Med Assoc J"},{"key":"R54-20250525","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.crohns.2010.10.006","article-title":"Pyoderma gangrenosum in inflammatory bowel disease: The experience at mater health services\u2019 adult hospital 1998-2009","volume":"5","author":"Polcz","year":"2011","journal-title":"J Crohns Colitis"},{"key":"R55-20250525","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/bmj.333.7560.181","article-title":"Diagnosis and treatment of pyoderma gangrenosum","volume":"333","author":"Brooklyn","year":"2006","journal-title":"BMJ"},{"key":"R56-20250525","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1159\/000111029","article-title":"Extraintestinal manifestations of Crohn\u2019s disease","volume":"76","author":"Juillerat","year":"2007","journal-title":"Digestion"},{"key":"R57-20250525","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1001\/archderm.1992.01680180054005","article-title":"Treatment of pyoderma gangrenosum with cyclosporine","volume":"128","author":"Matis","year":"1992","journal-title":"Arch Dermatol"},{"key":"R58-20250525","doi-asserted-by":"crossref","first-page":"219","DOI":"10.5217\/ir.2015.13.3.219","article-title":"Tacrolimus for the treatment of ulcerative colitis","volume":"13","author":"Matsuoka","year":"2015","journal-title":"Intest Res"},{"key":"R59-20250525","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1136\/gut.2005.074815","article-title":"Infliximab for the treatment of pyoderma gangrenosum: A randomised, double blind, placebo controlled trial","volume":"55","author":"Brooklyn","year":"2006","journal-title":"Gut"},{"key":"R60-20250525","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/ibd.20748","article-title":"Adalimumab treatment for peristomal pyoderma gangrenosum associated with Crohn\u2019s disease","volume":"15","author":"Alkhouri","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"R61-20250525","doi-asserted-by":"crossref","first-page":"E153","DOI":"10.1002\/ibd.21723","article-title":"Adalimumab for pyoderma gangrenosum associated with inflammatory bowel disease","volume":"17","author":"Cari\u00f1anos","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"R62-20250525","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.3748\/wjg.15.2293","article-title":"Successful use of adalimumab for treating fistulizing Crohn\u2019s disease with pyoderma gangrenosum: Two birds with one stone","volume":"15","author":"Zold","year":"2009","journal-title":"World J Gastroenterol"},{"key":"R63-20250525","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1572-0241.2006.00947.x","article-title":"Abnormal hepatic biochemistries in patients with inflammatory bowel disease","volume":"102","author":"Mendes","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"R64-20250525","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1055\/s-2008-1040541","article-title":"Hepatobiliary complications of inflammatory bowel disease","volume":"8","author":"Schrumpf","year":"1988","journal-title":"Semin Liver Dis"},{"key":"R65-20250525","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.dld.2010.01.011","article-title":"Update on primary sclerosing cholangitis","volume":"42","author":"Karlsen","year":"2010","journal-title":"Dig Liver Dis"},{"key":"R66-20250525","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1055\/s-2008-1040420","article-title":"Relationship of inflammatory bowel disease and primary sclerosing cholangitis","volume":"11","author":"Fausa","year":"1991","journal-title":"Semin Liver Dis"},{"key":"R67-20250525","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1053\/bega.2001.0204","article-title":"Epidemiology of primary sclerosing cholangitis","volume":"15","author":"Schrumpf","year":"2001","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"R68-20250525","doi-asserted-by":"crossref","first-page":"655","DOI":"10.3109\/00365528709011139","article-title":"Primary sclerosing cholangitis: A long-term follow-up study","volume":"22","author":"Aadland","year":"1987","journal-title":"Scand J Gastroenterol"},{"key":"R69-20250525","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jhep.2011.10.025","article-title":"Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: A systematic review","volume":"56","author":"Boonstra","year":"2012","journal-title":"J Hepatol"},{"key":"R70-20250525","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2214\/ajr.178.2.1780327","article-title":"Comparison of MR cholangiopancreatographic techniques with contrast-enhanced cholangiography in the evaluation of sclerosing cholangitis","volume":"178","author":"Vitellas","year":"2002","journal-title":"AJR Am J Roentgenol"},{"key":"R71-20250525","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/hep.20287","article-title":"Cost-minimization analysis of MRC versus ERCP for the diagnosis of primary sclerosing cholangitis","volume":"40","author":"Talwalkar","year":"2004","journal-title":"Hepatology"},{"key":"R72-20250525","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jhep.2009.04.009","article-title":"European Association for the Study of the Liver. EASL clinical practice guidelines: Management of cholestatic liver diseases","volume":"51","year":"2009","journal-title":"J Hepatol"},{"key":"R73-20250525","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/MCG.0b013e318157c614","article-title":"Characteristics and long-term prognosis of the autoimmune hepatitis\/primary sclerosing cholangitis overlap syndrome","volume":"43","author":"L\u00fcth","year":"2009","journal-title":"J Clin Gastroenterol"},{"key":"R74-20250525","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.jhep.2013.03.015","article-title":"Update on primary sclerosing cholangitis","volume":"59","author":"Karlsen","year":"2013","journal-title":"J Hepatol"},{"key":"R75-20250525","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1053\/j.gastro.2008.01.042","article-title":"The natural history of small-duct primary sclerosing cholangitis","volume":"134","author":"Bj\u00f6rnsson","year":"2008","journal-title":"Gastroenterology"},{"key":"R76-20250525","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1111\/liv.12492","article-title":"Small duct primary sclerosing cholangitis without inflammatory bowel disease is genetically different from large duct disease","volume":"34","author":"Naess","year":"2014","journal-title":"Liver Int"},{"key":"R77-20250525","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1111\/j.1572-0241.2003.07401.x","article-title":"Is there a role for liver biopsy in primary sclerosing cholangitis?","volume":"98","author":"Burak","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"R78-20250525","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1067\/mge.2002.125367","article-title":"Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: A meta-analysis","volume":"56","author":"Soetikno","year":"2002","journal-title":"Gastrointest Endosc"},{"key":"R79-20250525","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.1478-3231.2011.02575.x","article-title":"Malignancies and mortality in 200 patients with primary sclerosering cholangitis: A long-term single-centre study","volume":"32","author":"Fevery","year":"2012","journal-title":"Liver Int"},{"key":"R80-20250525","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1155\/2012\/426430","article-title":"Management of primary sclerosing cholangitis: Conventions and controversies","volume":"26","author":"Chandok","year":"2012","journal-title":"Can J Gastroenterol"},{"key":"R81-20250525","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1159\/000341123","article-title":"Primary sclerosing cholangitis: New approaches to diagnosis, surveillance and treatment","volume":"30 Suppl 1","author":"Trauner","year":"2012","journal-title":"Dig Dis"},{"key":"R82-20250525","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/hep.23082","article-title":"High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis","volume":"50","author":"Lindor","year":"2009","journal-title":"Hepatology"},{"key":"R83-20250525","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1055\/s-2006-933565","article-title":"Liver transplantation in primary sclerosing cholangitis","volume":"26","author":"Bj\u00f8ro","year":"2006","journal-title":"Semin Liver Dis"},{"key":"R84-20250525","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1586\/egh.10.33","article-title":"Treatment options for primary sclerosing cholangitis","volume":"4","author":"Sinakos","year":"2010","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"R85-20250525","first-page":"27","article-title":"Mesenteric venous thrombosis in inflammatory bowel disease","volume":"39","author":"Hatoum","year":"2005","journal-title":"J Clin Gastroenterol"},{"key":"R86-20250525","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/00005792-199209000-00001","article-title":"Amyloidosis and inflammatory bowel disease. A 50-year experience with 25 patients","volume":"71","author":"Greenstein","year":"1992","journal-title":"Medicine (Baltimore)"},{"key":"R87-20250525","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/00004836-199312000-00004","article-title":"Acute pancreatitis in Crohn\u2019s disease","volume":"17","author":"Weber","year":"1993","journal-title":"J Clin Gastroenterol"},{"key":"R88-20250525","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1212\/WNL.45.3.416","article-title":"Neurologic aspects of inflammatory bowel disease","volume":"45","author":"Lossos","year":"1995","journal-title":"Neurology"},{"key":"R89-20250525","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1177\/1352458511412996","article-title":"Inflammatory neurological disease in patients treated with tumor necrosis factor alpha inhibitors","volume":"17","author":"Solomon","year":"2011","journal-title":"Mult Scler"},{"key":"R90-20250525","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.cgh.2013.08.023","article-title":"Risk of cerebrovascular accidents and ischemic heart disease in patients with inflammatory bowel disease: A systematic review and meta-analysis","volume":"12","author":"Singh","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R91-20250525","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.crohns.2013.09.021","article-title":"Thromboembolic events and cardiovascular mortality in inflammatory bowel diseases: A meta-analysis of observational studies","volume":"8","author":"Fumery","year":"2014","journal-title":"J Crohns Colitis"},{"key":"R92-20250525","doi-asserted-by":"crossref","first-page":"e56944","DOI":"10.1371\/journal.pone.0056944","article-title":"Disease activity in inflammatory bowel disease is associated with increased risk of myocardial infarction, stroke and cardiovascular death \u2013 A Danish nationwide cohort study","volume":"8","author":"Kristensen","year":"2013","journal-title":"PLoS One"},{"key":"R93-20250525","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/00054725-200303000-00004","article-title":"Pulmonary manifestations of inflammatory bowel disease","volume":"9","author":"Storch","year":"2003","journal-title":"Inflamm Bowel Dis"},{"key":"R94-20250525","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1136\/gut.27.8.919","article-title":"Latent pulmonary involvement in Crohn\u2019s disease: Biological, functional, bronchoalveolar lavage and scintigraphic studies","volume":"27","author":"Bonniere","year":"1986","journal-title":"Gut"},{"key":"R95-20250525","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1046\/j.1365-2222.1999.00508.x","article-title":"Bronchial eosinophilic infiltration in Crohn\u2019s disease in the absence of pulmonary disease","volume":"29","author":"Louis","year":"1999","journal-title":"Clin Exp Allergy"},{"key":"R96-20250525","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.crohns.2010.03.008","article-title":"Pulmonary manifestations of inflammatory bowel disease: Case presentations and review","volume":"4","author":"Basseri","year":"2010","journal-title":"J Crohns Colitis"},{"key":"R97-20250525","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/ibd.21468","article-title":"Renal manifestations and complications of inflammatory bowel disease","volume":"17","author":"Oikonomou","year":"2011","journal-title":"Inflamm Bowel Dis"}],"container-title":["Saudi Journal of Medicine &amp; Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01797456-201907020-00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:06:19Z","timestamp":1787774779000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01797456-201907020-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,12]]},"references-count":97,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.4103\/sjmms.sjmms_81_18","relation":{},"ISSN":["1658-631X","2321-4856"],"issn-type":[{"value":"1658-631X","type":"print"},{"value":"2321-4856","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,12]]}}}